Conference Proceedings

Phase I expansion cohort results of cemiplimab, a human PD-1 monoclonal antibody, in combination with radiotherapy (RT), cyclophosphamide and GM-CSF, in patients (pts) with recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)

HM Babiker, I Brana, D Mahadevan, TK Owonikoko, E Calvo, D Rischin, V Moreno, KP Papadopoulos, M Crittenden, S Formenti, J Giralt, P Garrido Lopez, A Hervas Moron, KK Mohan, MG Fury, I Lowy, E Stankevich, M Feng, J Li, M Mathias

Annals of Oncology | OXFORD UNIV PRESS | Published : 2018


Funding Acknowledgements

Regeneron Pharmaceutical, Inc.; Sanofi.